CHA2DS2-VASc Score as a Predictor of New Onset Atrial Fibrillation in Patients With Non-ST Segment Elevation Myocardial Infarction Who Underwent Percutaneous Coronary Intervention

Abstract

Background: New-onset atrial fibrillation (NOAF) often complicates acute coronary syndromes (ACSs) with adverse short- and long-term consequences. However, the current risk classification model for estimating NOAF during non-ST-segment elevation myocardial infarction (NSTEMI) remains unclear. Some parameters in the CHA2DS2-VASc score are closely related to the development of atrial fibrilation (AF). Methods: This retrospective study was conducted among 670 consecutive NSTEMI patients who applied to our cardiovascular center between June 2020 and June 2022 and underwent percutaneous coronary intervention (PCI). Results: NOAF developed during hospitalization in 55 patients (12.5%). NOAF patients were older and had higher high sensitivity C-reactive protein (hs-CRP), left atrial volume index, Post PCI thrombolysis in myocardial infarction (TIMI) grade <3, CHA2DS2-VASc score, peak troponin I (ng/ml), and SYNTAX score (SS). After univariate logistic regression analysis for the predictors of NOAF development, CHA2DS2-VASc score, post PCI TIMI grade <3, hemoglobin, hsCRP, SS alone were predictors of NOAF, but after multivariate analysis, CHA2DS2-VASc score, post PCI TIMI grade <3, hemoglobin had a determining effect. Conclusions: The CHA2DS2-VASc score can be evaluated as a predictor of NOAF after PCI in NSTEMI. Except for the components of the CHA2DS2-VASc score, post PCI TIMI grade <3 and low hemoglobin levels are independent risk factors for NSTEMI-NOAF.